ImmunityBio (IBRX) Other financing activities (2014 - 2026)

ImmunityBio (IBRX) has 10 years of Other financing activities data on file, last reported at $53.5 million in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $53.5 million in Q1 2026; TTM through Mar 2026 was $53.5 million, a 21.7% decrease from a year earlier, with the FY2024 full-year figure at $73.3 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at $53.5 million, up from $15.6 million in the prior quarter.
• Over the last five years, Other financing activities for IBRX reached as high as $53.5 million in Q1 2026 and fell as low as -$126000.0 in Q2 2023.
• Historically, Other financing activities has averaged $17.0 million across 4 years, with a median of $7.1 million in 2023.
• Across the five-year window, Other financing activities tumbled 93.4% in 2022 and jumped 41976.19% in 2024, its largest moves.
• Year by year, Other financing activities stood at -$74000.0 in 2022, then slumped by 70.27% to -$126000.0 in 2023, then soared by 12494.44% to $15.6 million in 2024, then surged by 242.84% to $53.5 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $53.5 million in Q1 2026, $15.6 million in Q3 2024, and $52.8 million in Q2 2024.